Sucralfate versus placebo in treatment of non-ulcer dyspepsia

Kairaluoma, Matti I.; Hentilae, Risto; Alavaikko, M; Kellosalo, Juhani; Ståhlberg, M; Jalovaara, P.; Olsen, Matti; Jaervensivu, Pekka; Laitinen, S

doi:10.1016/0002-9343(87)90828-x

Cited by 32 publications

(15 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…75 Evidence from randomised trials has again been conflicting and, in the case of bismuth salts, has been compounded by the possibility that their effect may be due to suppression of H. pylori. 76,77 Evidence for disorders of gastroduodenal motility…”

Section: Evidence For Gastric Acid Secretion Abnormalitiesmentioning

confidence: 99%

“…There was also no evidence that sucralfate was superior to placebo from a metaanalysis of two trials ( Figure 13). 76,197 A further trial (28 patients), in which global symptoms were reported as a continuous outcome measure, also found no difference between sucralfate and placebo (symptom score improved by a mean of 0.8 in the placebo group compared with the sucralfate group; 95% CI, -0.83 to 2.43). …”

mentioning

confidence: 94%

See 1 more Smart Citation

The management of dyspepsia: a systematic review.

Delaney

Moayyedi²,

Deeks³

et al. 2000

Health Technology Assessment

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Competing interests: R Hobbs is a board member of the European Society of Primary Care Gastroenterology, and has received sponsorship for travel and honoraria from a number of biotechnology and pharmaceutical companies for plenary talks and attendance at major scientific congresses and conferences. HTA Published end of 2000This report should be referenced as follows:Delaney B, Moayyedi P, Deeks J, Innes M, Soo S, Barton P, et al. NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and ...

show abstract

Section: Evidence For Gastric Acid Secretion Abnormalitiesmentioning

confidence: 99%

mentioning

confidence: 94%

The management of dyspepsia: a systematic review.

Delaney

Moayyedi²,

Deeks³

et al. 2000

Health Technology Assessment

View full text Add to dashboard Cite

show abstract

“…Studies evaluating the efficacies of cytoprotective agents in the treatment of nonulcer dyspepsia and nonerosive gastritis have generally found them to be equally or marginally more efficacious than placebo [42, 43]. Interestingly, randomized clinical trials comparing cytoprotective agents with the acid-suppressive agent, Ranitidine, have observed superior efficacy with the former [44, 45].…”

Section: Discussionmentioning

confidence: 99%

Troxipide in the Management of Gastritis: A Randomized Comparative Trial in General Practice

Dewan¹,

Balasubramanian²

2010

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Background. A trial of empirical acid-suppressive therapy is the usual practice for most patients with symptoms of gastritis in primary care. Aim. To assess the relative efficacy of Troxipide and Ranitidine in patients with endoscopic gastritis over a four-week period. Methods. In all, 142 patients were randomized to Troxipide (100 mg tid) or Ranitidine (150 mg bid) for a period of four weeks. The severity of the signs of endoscopic gastritis at baseline and week 4 using a four-point scale and the subjective symptom severity at baseline and week 2 & week 4 using a Visual analog scale (VAS) were documented. Results. Troxipide was found to be superior to Ranitidine for both, the complete resolution and improvement of endoscopic gastritis. Higher proportion of patients showed complete healing of erosions (88.14%), oozing (96.77%), and edema (93.88%) with Troxipide as compared to Ranitidine (P < .01). Patients receiving Troxipide also showed a greater improvement in the VAS scores for abdominal pain, bloating, and heartburn (P < .01). Both the drugs were found to be well tolerated. Conclusion. In patients with endoscopic gastritis, Troxipide, with its superior rate of improvement, resolution of signs, and subjective clinical symptoms, can be considered as an alternative to the commonly used antisecretory agents.

show abstract

“…Although unconfirmed, a positive net effect has been demonstrated in functional dyspepsia in one study (57). In addition, sucralfate is reasonably effective in peptic ulcer and gastroesophageal reflux disease.…”

Section: Sucralfatementioning

confidence: 91%

Therapeutic Trial in Dyspepsia: Its Role in the Primary Care Setting

Nyrén

1991

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

Sucralfate versus placebo in treatment of non-ulcer dyspepsia

Cited by 32 publications

References 6 publications

The management of dyspepsia: a systematic review.

The management of dyspepsia: a systematic review.

Troxipide in the Management of Gastritis: A Randomized Comparative Trial in General Practice

Therapeutic Trial in Dyspepsia: Its Role in the Primary Care Setting

Contact Info

Product

Resources

About